236 related articles for article (PubMed ID: 11465391)
1. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline.
Murray S; Odupitan AO; Murray BP; Boobis AR; Edwards RJ
Xenobiotica; 2001 Mar; 31(3):135-51. PubMed ID: 11465391
[TBL] [Abstract][Full Text] [Related]
2. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
3. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
5. Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes.
Nakajima M; Kobayashi K; Oshima K; Shimada N; Tokudome S; Chiba K; Yokoi T
Xenobiotica; 1999 Sep; 29(9):885-98. PubMed ID: 10548449
[TBL] [Abstract][Full Text] [Related]
6. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.
Feierman DE; Lasker JM
Drug Metab Dispos; 1996 Sep; 24(9):932-9. PubMed ID: 8886601
[TBL] [Abstract][Full Text] [Related]
8. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
9. Effects of propofol on human hepatic microsomal cytochrome P450 activities.
McKillop D; Wild MJ; Butters CJ; Simcock C
Xenobiotica; 1998 Sep; 28(9):845-53. PubMed ID: 9764927
[TBL] [Abstract][Full Text] [Related]
10. Human cytochrome P450s: selectivity and measurement in vivo.
Smith DA; Abel SM; Hyland R; Jones BC
Xenobiotica; 1998 Dec; 28(12):1095-128. PubMed ID: 9890156
[No Abstract] [Full Text] [Related]
11. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
[TBL] [Abstract][Full Text] [Related]
12. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro.
Störmer E; Brockmöller J; Roots I; Schmider J
Psychopharmacology (Berl); 2000 Sep; 151(4):312-20. PubMed ID: 11026737
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Grimm SW; Dyroff MC
Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
[TBL] [Abstract][Full Text] [Related]
15. Polysaccharide peptides from Coriolus versicolor competitively inhibit model cytochrome P450 enzyme probe substrates metabolism in human liver microsomes.
Yeung JH; Or PM
Phytomedicine; 2012 Mar; 19(5):457-63. PubMed ID: 22305191
[TBL] [Abstract][Full Text] [Related]
16. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
[TBL] [Abstract][Full Text] [Related]
17. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
18. Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes.
Kobayashi K; Nakajima M; Oshima K; Shimada N; Yokoi T; Chiba K
Drug Metab Dispos; 1999 Aug; 27(8):860-5. PubMed ID: 10421611
[TBL] [Abstract][Full Text] [Related]
19. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
[TBL] [Abstract][Full Text] [Related]
20. CYP2C9 is a principal low-affinity phenacetin O-deethylase: fluvoxamine is not a specific CYP1A2 inhibitor.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 1999 Dec; 27(12):1519-22. PubMed ID: 10627170
[No Abstract] [Full Text] [Related]
[Next] [New Search]
